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and CZ, while PL references to all EU countries. CZ and RO employ the average
among the three lowest reference prices and BG and PL the lowest reference price.
There is a regressive margin scale in all countries. In BG, RO and PL margins are
separated for wholesalers and retailers, while in CZ they are negotiated. In CZ and
PL there are multiple insurance companies compared to BG and RO, where there is
only one. Currently RO’s reimbursement is 50% of the price for all prescription
drugs, BG and PL use 4 reimbursement levels, PL and CZ employ a complex external
and internal referencing. In CZ the reimbursement base is the cheapest medicinal
price in the group. In BG, PL and RO the reimbursement level is the cheapest price
per DDD for every INN. All countries require pharmacoeconomic evidences, but CZ
and PL employ guidelines, while BG and RO apply criteria for evaluation.
CONCLUSIONS: We deem BG and RO systems less adaptable, but clearer to follow.
CZ and PL systems show greater flexibility, due to existence of negotiation and
freedom.
Individual’s Health – Research on Methods
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THE KIGS QUALITY INSIGHT PROGRAM ASSESSING THE QUALITY OF CARE FOR
SHORT CHILDREN TREATED WITH GROWTH HORMONE USING THE OUTPUT
FROM A LARGE PHARMACO-EPIDEMIOLOGICAL SURVEY
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OBJECTIVES: Despite nearly 25 years of experience with recombinant human
growth hormone (GH) treatment modalities vary significantly between centres and
regions and final outcome of GH therapy varies widely . In a country like Germany,
for example, children with growth disorders are treated with Genotropin® (Pfizer
Inc, New York) in more than 150 institutions with different levels of experience.
METHODS: Data collected from more than 75,000 children with growth disorders
treated with Genotropin are followed-up worldwide in a large, pharmaco-epidemi-
ological database (KIGS, Pfizer International Growth Study). Country specific data-
sets are used to compare treatment standards and demonstrate differences be-
tween individual centres and the country as a whole. Site-specific, individualized
reports enable clinicians to anonymously benchmark the quality of care in their
treatment centre. Quality indicators (like diagnostic tests, height and height veloc-
ity, GH dose, treatment response and responsiveness, treatment duration, adverse
events, completeness of documentation) are followed and compared. RESULTS:
Structural aspects as well as process and outcome indicators differed between the
paediatric endocrinology centres, e.g. age at start of therapy, GH doses and diag-
nostic procedures. The reports allowed self-audit of clinical practice, sharing of
best practice and promote discussion of clinical decision making in paediatric
specialist care forums. CONCLUSIONS: The KIGS Quality Insight (KIGS QI) program
provides a successful approach to unmask deficits and to improve the outcome of
care. The output from the centre and country specific analysis allows identification
and follow-up of GH non-responders and assists with demonstration of standard of
care and treatment outcomes in the country to hospital managers, guidelines com-
mittees and payers. Results from KIGS can be successfully used to enable investi-
gators to compare their treatment centre with the country as a whole and to assess
changes over time.
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FEMALE URINARY INCONTINENCE IN GERMANY– COST EXPLOSION
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OBJECTIVES: To estimate costs of routine care for female urinary incontinence in
nursing care in Germany. The management of female urinary incontinence is con-
sidered as the most cumbersome task in nursing homes for the elderly. Despite the
great economic burden of incontinence, the largest cost category, routine care
costs, is poorly described, and there are limited data on cost in nursing homes
METHODS: In cooperation with a nursing home, cost of managing incontinent
patients was evaluated. Both direct patient-material and laundry costs were con-
sidered. Time required to manage an incontinent patients was also evaluated. Data
were collected on randomly selected female patients. The determination of the
cost was based on the existing prices and the usual salary of employees in nursing
homes. RESULTS: Total cost of managing an incontinent patient sums up to
€2260.06/month/patient. Cost calculation of nursing care was based on a 4 times/
day changing of diapers. This accounted in total €434.40 for the material costs
(anatomical pads, disposable gloves, hand and surface disinfectants, incontinence
bed cover, mattress protectors, pants, wound cream, protective aprons and dia-
pers). The costs for the nursing staff work amounted to €1825.66. The results are in
contrast to the publication of Schulenburg et. al who analyzed the material costs in
German Health Care System by incontinence patients. The annual costs were cal-
culated with 261 €. Personnel costs were not calculated. CONCLUSIONS: Female
urinary incontinence demands highest attention and should not be taken as symp-
tom of aging. Rather, the urinary incontinence is treatable disease, which improves
the quality of life and reduces the cost of health care. Female urinary incontinence
should be perceived as a widespread disease. Approaches would include the de-
velopment of a disease management program and the implementation in German
social act.
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OBJECTIVES:Neisseria meningitidis (Nm) is a leading cause of bacterial meningitis
and bacteremia worldwide. While infection (or carriage) is common throughout a
person’s life history, invasive meningococcal disease (IMD) is rare and is dispro-
portionately observed in infants and adolescents. Previous models that evaluated
the health and economic impact of meningococcal vaccines have not always con-
sidered key epidemiological features such as transmission mechanisms, or risk of
IMD outbreaks. Our objective was to understand which natural history assump-
tions best matched the observed time trends in disease notification data, in order to
use the most realistic model to economically evaluate new meningococcal vacci-
nation policies. METHODS: We formulated two dynamic stochastic compartmen-
tal models of Nm transmission within a population of hosts: the first assumed
transient natural immunity entailing perfect cross-protection between serogroups;
the second assumed partial (and thus imperfect) cross-immunity amongst sero-
groups. In both models, Nm infection and IMD were assumed to be distinct sto-
chastic processes and IMD was assumed to occur in a small fraction of the popu-
lation at the time infection is acquired. RESULTS: Model parameters were
calibrated to carriage data and 62-year case notification data from Canada. Sus-
tained oscillations and co-circulation of multiple serogroups are ubiquitous in the
IMD case notification data of many countries. Only the second model captured
these patterns, while the first model unrealistically predicted that one serogroup
would always disappear from the population. CONCLUSIONS: The predicted im-
pact of various meningococcal vaccines will likely depend strongly on assumptions
about strain interactions, some of which lead to dynamics that are inconsistent
with observations. While empirical unknowns about strain interactions between
Nm serogroups remain, our results suggest that cross-protection and natural im-
munity assumptions significantly impact predicted multigroup dynamics, and
hence may affect predictions of the health and economic impact of new vaccina-
tion policies.
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TRAIT OR STATE: AN EXPLORATION OF SELF-ESTEEM, HAPPINESS AND
QUALITY OF LIFE BY TIME SERIES
Yang JJ, Yao G
National Taiwan University, Taipei, Taiwan
OBJECTIVES: Mainstream of psychological researches usually utilizes large sam-
ples, cross-sectional studies and aggregate frames to analyze data and interpret
them. However, the limitations are that the specific features of individuals are not
easy to be revealed and the time effect has been ignored. This study explores both
of the trait-like and state-like properties including global self-esteem, happiness
and the quality of life. By using time series analysis which can examine individual,
longitudinal and non-aggregate data, the properties of psychological measures can
be investigated. METHODS: Ten college students (mean age20.6 year, SD2.18)
and four adults (mean age30.27 year, SD1.23) participated in this study. Each
subject completed six 10-cm visual analogue scale items, once a day for 2 months.
These items measure subject’s global self-esteem, happiness, the quality of life,
positive life events, negative life events as well as random error (i.e., Participant
was asked to make a mark on the center of a line). Time series analysis, including
autoregressive and moving average modeling procedures, was used to examine the
time dependency (i.e., more trait-like) for each item. RESULTS: For the college
sample, 80% of autocorrelation and partial-autocorrelation coefficients were not
significant across time lag. This result doesn’t fully support the existence of time
dependency for each item. On the contrary, 55% of autocorrelation and partial-
autocorrelation coefficients were statistically significance for the adult sample.
Both samples showed significant correlations among psychological measures (self-
esteem, happiness and the quality of life) and life events (positive and negative).
CONCLUSIONS: In conclusion, the results support that self-esteem, happiness and
quality of life may contain both trait-like and state-like properties, and the time
dependency of psychological measures is more stable especially in adults.
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OBJECTIVES: Annual growth prediction models following growth hormone (GH)
treatment have been developed to facilitate treatment guidance. However, accu-
rately predicting height over the long term, during pre-pubertal treatment years
has not been assessed and is a prerequisite for modelling of cost effective optimum
height outcomes. METHODS: Annual prediction models utilised data from large
cohorts sourced from the KIGS database (Pfizer International Growth Database,
comprising 75,000 children with growth disorders) and describe the likely annual
height gain based on patients’ auxological and biochemical characteristics (e.g. GH
dose, age, mid parental height standard deviation [SDS] and weight SDS score) at
treatment start. The most likely long-term height development was simulated
prospectively up to 4 years by sequential application of existing yearly prediction
algorithms for height velocity (HV) and newly developed algorithms for weight gain
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in pre-pubertal children with idiopathic GH Deficiency (GHD) and Turner Syn-
drome (TS). The long-term prediction of height was validated in new cohorts of
pre-pubertal children with GHD (n 664) or TS (n607) from KIGS. RESULTS:When
height was simulated from GH start in GHD, the predicted mean (SD) gain after 4
years was 30.4 (3.4) cm; the observed height gain was 30.0 (5.0) cm. In TS the
corresponding predicted and observed mean gains were 27.2 (2.2) and 26.5 (3.8) cm.
CONCLUSIONS: Sequential application of annual KIGS growth prediction models
permits accurate simulation of height development during the first four years of
GH treatment in GHD and TS and is applicable for patient groups from GH start.
Long-term growth simulation helps managing patient’s expectations and facili-
tates an individualised, cost effective growth hormone (GH) therapy in children.
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OBJECTIVES: To establish whether there are subsets of women with idiopathic
menorrhagia who experience differential health-related quality of life (HRQL) ben-
efits with LNG-IUS treatment, and which factors could be attributed to those
differences. METHODS: Data for women with idiopathic menorrhagia residing in
India, Russia and Turkey were derived from a prospective, 12-month observational
study. Latent profile analysis (LPA) was used to identify unknown subgroups of
differential responders on the Mental Component Summary (MCS) of the SF-36v2.
Post hoc analyses were performed to characterize identified subgroups using base-
line and 12 month data. RESULTS: Overall improvement in MCS scores from base-
line to 12 months was 8.4 points. LPA analyses revealed two distinct subsets of
patients: one smaller subset (30% of the sample) showed a smaller improvement
(2.3 points) than the improvement overall and are thus referred to as ‘partial-
responders.’ A larger subgroup (70% of the sample) was identified with a much
greater improvement (11.3 points) than that overall, thus referred to as ‘respond-
ers’. Post hoc analyses revealed statistically significant differences between MCS
responders and partial-responders: significantly greater proportion of MCS re-
sponders had university-level education, were more likely to reside in India or
Russia and be employed, reported‘none’ or ‘light’ bleeding intensity while on treat-
ment, reported greater patient and physician satisfaction with treatment, and had
higher 12-month haemoglobin levels. CONCLUSIONS: Understanding of heteroge-
neity of treatment response is critical for routine clinical practice. Application of
LPA identified two distinct subgroups of women showing differential response to
HRQL from LNG-IUS treatment. All women showed a statistically significant im-
provement in HRQL as measured by the MCS, although this improvement was
greater for a large subset of women in the sample. Country-level differences in
treatment effect on mental HRQL may be subject to cultural or health care practice
differences.
Systemic Disorders/Conditions – Clinical Outcomes Studies
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OBJECTIVES: To evaluate the tolerability of oral long-acting opioids (LAOs) in pa-
tients treated for chronic pain. Opioid analgesia is the mainstay of treatment for
moderate to severe chronic pain. While highly effective in relieving pain, it is
limited by adverse events (AEs), especially gastrointestinal and central nervous
system events. AEs may result in additional treatment costs and discontinuation of
therapy, compromising pain management.METHODS:A systematic review of Eng-
lish-language literature published through February 2009 was performed. Random-
ized controlled trials comparing commonly used oral schedule II LAOs with placebo
or another opioid were included. Data on pain measures and pre-specified AEs
(nausea, vomiting, somnolence, constipation, headache, pruritus, and dry mouth)
were collected from each study. For descriptive statistics, treatment-arm data on
tapentadol, oxycodone, oxymorphone, morphine, hydromorphone, and placebo
were pooled across trials. Direct and indirect meta-analyses were performed to
compare AE rates of individual LAOs with placebo and with tapentadol. RESULTS:
Seventy-one published studies met the inclusion criteria. Tapentadol was associ-
ated with the lowest incidence of AEs across the 5 LAOs, with the exception of
headache and dry mouth. The AE incidences for tapentadol, oxycodone, oxymor-
phone, morphine, hydromorphone, and placebo were: nausea: 19.5%, 32.5%, 38.8%,
29.7%, 33.5%, and 8.4%, respectively; vomiting: 7.9%, 16.1%, 19.9%, 15.5%, 15.1%, and
2.4%; somnolence: 10.2%, 24.8%, 18.3%, 33.6%, 50.4%, and 3.7%; constipation: 14.1%,
34.7%, 26.9%, 43.2%, 27.6%, and 6.1%; headache: 13.3%, 11.3%, 9.7%, 3.8%, 5.7%, and
10.4%; pruritus: 5.2%, 16.6%, 15.7%, 20.1%, 20.8%, and 1.5%; and dry mouth: 6.8%,
11.8%, 10.0%, 31.4%, and 2.6% (placebo), with no data for hydromorphone. Indirect
meta-analyses further revealed a significantly favorable tolerability profile of tap-
entadol when compared to oxycodone, oxymorphone, and morphine.
CONCLUSIONS: Opioid-associated AEs are common, but the incidence varied
across the LAOs reviewed. Indirect meta-analyses suggest that tapentadol has a
better tolerability profile than other LAOs.
PSY2
COEXISTENCE OF IMMUNO-MEDIATED INFLAMMATORY DISEASES: AN
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OBJECTIVES: Immuno-mediated inflammatory diseases (IMIDs) may coexist
within the same patient. Anti-TNFs have been shown to be effective at treating
IMIDs. The present study aimed at evaluating the prevalence of the coexistence of
selected IMIDs and other comorbidities, characterizing the patient population and
assessing the use of anti-TNFs from a populational standpoint. METHODS: A co-
hort of patients who had received at least one diagnosis of rheumatoid arthritis
(RA), ankylosing spondylitis, psoriatic arthritis, psoriasis (Ps), Crohn’s disease (CD),
ulcerative colitis, or uveitis, between January 2005 and December 2009, was ran-
domly selected from the Régie de l’assurance-maladie du Québec (RAMQ) data-
bases. The coexistence and temporality of the above diagnoses as well as other
predefined chronic conditions were assessed. Characterization and stratification
according to demographics and anti-TNF use (use or no-use) were also performed.
RESULTS: A total of 80,566 patients who had at least one diagnosis of an IMID were
included in this cohort. The study population was on average 53.6 years old (SD:
21.3 years) and was in majority female (60,1%). Most common primary diagnoses
were RA (33.4%), Ps (33.8%) and CD (22.8%) while 3.9% of patients had received at
least one prescription of an anti-TNF medication. In this population, 9.1% of pa-
tients presented with one coexisting IMID diagnosis and 1.4% with 2 or more coex-
isting diagnoses. Among patients who had used an anti-TNF, 27.9% had one coex-
isting IMID diagnosis and 9.1% had 2 or more coexisting diagnoses. Other chronic
comorbidities were found in 82.8% of patients. The most frequent comorbidities
were hypertension (37.2%), cardiovascular diseases (22.4%), diabetes (16.7%) and
osteoporosis (15.7%).CONCLUSIONS:Coexisting IMID diagnoses and comorbidities
are often present in patients with IMID and greatly contribute to the burden of
disease.
PSY3
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OBJECTIVES: Obesity is considered a major Public Health issue in most developed
countries nowadays for its wide spread across population groups, as well as its
contribution to the development of chronic diseases. Our objective was to estimate
and better understand the impact of progressively increasing Body Mass Index
(BMI) on diagnosed Diabetes, Heart Attack (HA), Hypertension, Chronic Anxiety
(CA) and Chronic Depression (CD) in adult population. METHODS: Retrospective
analysis of the Spanish 2009 European Health Survey System data base was con-
ducted. Data from population under 18 years old or with BMI under 18.5 or with not
reported BMI were excluded. Sample size of 19,880 adults (89.6% of the initial sam-
ple) was available for analysis. A logistic regression model was constructed for each
of the five dependent variables. Age groups were divided by quartiles. BMI groups
were “18.5–24.9”, “25–29.9”, “30–34.9” (g3) and “35 or more”(g4). RESULTS: Diabetes
prevalence was 7.7%; (OR adjusted for g3:2.3; 95% CI: 2.0–2.7; OR_g4: 4.2; CI:3.4-5.3),
Hypertension prevalence was 23.6%; (OR_g3: 3.4; CI:3.0–3.8; OR_g4: 5.8; CI: 4.8–6.9),
HA prevalence was 2.8%; (OR_g3: 1.7; CI: 1.3–2.1; OR_g4: 1.6; CI: 1.1–2.5), CA preva-
lence was 8.2%; (OR_g3: 1.6; CI: 1.3–1.8; OR_g4: 2.3; CI: 1.8–2.9), CD prevalence was
7.9%; (OR_g3: 1.7; CI: 1.4–2.0; OR_g4: 2.7; CI: 2.2–3.4). All the stated OR reached
statistical significance (p0.05 for OR_g4 in HA and p0.001 for all the rest of them).
CONCLUSIONS: The results show how the risk of the examined comorbidities
largely increases in those patients with BMI35. Considering its potential econom-
ical impact on Public Health, it would be required to design and implement effec-
tive strategies aimed at the early detection of subjects at risk and the provision of
adequate treatment, as well as to establish suitable preventive programmes.
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OBJECTIVES: No direct comparisons have been made between infliximab and
ustekinumab in the treatment of moderate to severe psoriasis. A mixed treatment
comparative (MTC) meta-analysis was conducted to compare the relative efficacy
of infliximab and ustekinumab for the treatment of moderate to severe plague
psoriasis. METHODS: Randomized clinical trials that included infliximab, 5 mg/kg,
ustekinumab 45 mg or ustekinumab 90 mg in the treatment arm and reported PASI
75 and PASI 90 endpoints were identified from a systematic literature search. The
log odds ratio (log OR) was used as the treatment effect measure using both fixed-
effects and random-effects MTC models. Six trials meeting the inclusion criteria
were included in the mixed treatment networks to estimate relative efficacy.
RESULTS: The pooled odds ratio of achieving PASI 75 was 164.4 (95% (CI): 78.3 –
330.1) for infliximab, 77.9 (95% CI: 49.3 - 121.1) for ustekinumab 90 mg and 59.8 (95%
CI: 37.9 - 92.3) for ustekinumab 45 mg compared to placebo. Pairwise comparison
suggested that infliximab is significantly better than and ustekinumab 45 mg to
achieve PASI 75 (p 0.05). Pooled odds ratio of achieving PASI 90 was 172.6 (95% CI:
46.7 - 525.2) for infliximab, 79.6 (95% CI: 39.2 - 155.2) for ustekinumab 90 mg and 65.5
(95% CI: (32.1 - 127.8) for ustekinumab 45 mg. Similarly, there was a statistically
significant difference between infliximab and ustekinumab 45 mg in attaining PASI
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